Page 1 | Search Results | Blood | American Society of Hematology

1-4 of 4

Sort by

Sort Order Select

Journal Articles

Delta opioid receptor (DOR): A novel target for reprogramming tumor-associated macrophage (TAM) immunosuppressive phenotype to overcome acquired resistance and enhance the effectiveness of cancer immunotherapies

KRIT Ritthipichai, Ian Frank, Edward Garcia, Maya Jerald, Pingyan Cheng, Ruihua Chen, Tiffany Razabdouski, Erika Eksioglu, Bertrand Le Bourdonnec, Thierry Guillaudeux, James Bianco

Blood (2025) 146 (Supplement 1): 1201.

https://doi.org/10.1182/blood-2025-1201

Published: 2025

Journal Articles

Delta opioid receptor (DOR) expression on myeloid-derived suppressor cells (MDSCs) represents a novel target to overcome resistance to immune checkpoint inhibitors (ICIs)

Pingyan Cheng, Maya Jerald, Ian Frank, Edward Garcia, KRIT Ritthipichai, Ruihua Chen, Erika Eksioglu, Tiffany Razabdouski, Arjun Jayakrishnan, Bertrand Le Bourdonnec, Thierry Guillaudeux, James Bianco

Blood (2025) 146 (Supplement 1): 622.

https://doi.org/10.1182/blood-2025-622

Published: 2025

Journal Articles

Expansion and Characterization of Iovance Marrow Infiltrating Lymphocytes: A Potential Novel Therapeutic Strategy for the Treatment of Acute Myeloid Leukemia

Lavakumar Karyampudi, PhD, Ian Frank, Michelle Blaskovich, John C. Byrd, MD, Cecile Chartier, Meixiao Long, MD

Blood (2018) 132 (Supplement 1): 5683.

https://doi.org/10.1182/blood-2018-99-114825

Published: 2018

Journal Articles

Differential Th17 CD4 T-cell depletion in pathogenic and nonpathogenic lentiviral infections

Jason M. Brenchley, Mirko Paiardini, Kenneth S. Knox, Ava I. Asher, Barbara Cervasi, Tedi E. Asher, Phillip Scheinberg, David A. Price, Chadi A. Hage, Lisa M. Kholi, Alexander Khoruts, Ian Frank, James Else, Timothy Schacker, Guido Silvestri, Daniel C. Douek

Blood (2008) 112 (7): 2826–2835.

https://doi.org/10.1182/blood-2008-05-159301

Published: 2008

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Delta opioid receptor (DOR): A novel target for reprogramming tumor-associated macrophage (TAM) immunosuppressive phenotype to overcome acquired resistance and enhance the effectiveness of cancer immunotherapies

Delta opioid receptor (DOR) expression on myeloid-derived suppressor cells (MDSCs) represents a novel target to overcome resistance to immune checkpoint inhibitors (ICIs)

Expansion and Characterization of Iovance Marrow Infiltrating Lymphocytes: A Potential Novel Therapeutic Strategy for the Treatment of Acute Myeloid Leukemia

Differential Th17 CD4 T-cell depletion in pathogenic and nonpathogenic lentiviral infections

Email alerts

ASH Publications

American Society of Hematology

Update search

Delta opioid receptor (DOR): A novel target for reprogramming tumor-associated macrophage (TAM) immunosuppressive phenotype to overcome acquired resistance and enhance the effectiveness of cancer immunotherapies

Delta opioid receptor (DOR) expression on myeloid-derived suppressor cells (MDSCs) represents a novel target to overcome resistance to immune checkpoint inhibitors (ICIs)

Expansion and Characterization of Iovance Marrow Infiltrating Lymphocytes: A Potential Novel Therapeutic Strategy for the Treatment of Acute Myeloid Leukemia

Differential Th17 CD4 T-cell depletion in pathogenic and nonpathogenic lentiviral infections

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only